Shaowei Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shaowei Zheng has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Chunhan Sun
Department of Orthopaedics, Huizhou First Hospital, Guangdong Medical University, Huizhou, China
3 shared publications- Chun-Yan Shen
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China; Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, Southern Medical University, Guangzhou 510515, China; Guangdong Basic Research Center of Excellence for Integrated Traditional and Western Medicine for Qingzhi Diseases, Guangzhou 510515, China
2 shared publications - Chunhan Sun
Department of Orthopaedics Huizhou First Hospital Guangdong Medical University Huizhou China
2 shared publications Ding Wang
Department of Orthopedic, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China
2 shared publications- Hao Cheng
Department of Orthopaedics Nanfang Hospital Southern Medical University Guangzhou China
2 shared publications Hao Li
Department of Orthopedic, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China
2 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (40) , e71772
Cooperative Stem Cell Homing and Photothermal Protection Driven by an Injectable Hydrogel for Bone‐Vascular Regeneration
Bone defects caused by trauma or disease present significant clinical challenges, necessitating advanced biomaterials that simultaneously recruit stem cells and orchestrate a conducive microenvironment for repair. Here, we present an injectable hydrogel system designed to drive integrated bone‐vascular regeneration through targeted stem cell homing and localized metabolic rescue. The composite hydrogel, crosslinked from gelatin and oxidized starch, integrates liposome‐encapsulated stromal cell‐derived factor‐1 (SDF‐1) and MXene‐enabled GelMA microspheres. This minimally invasive system addresses two critical regenerative phases. First, liposomal SDF‐1 undergoes controlled release to effectively recruit endogenous bone marrow mesenchymal stem cells (BMSCs). Concurrently, under near‐infrared irradiation, the MXene‐GelMA microspheres generate mild localized heat stress (40—42 °C). Crucially, this targeted photothermal therapy acts as a metabolic rescue mechanism; it upregulates heat shock protein 70 (HSP70) in BMSCs to mitigate apoptosis, stimulating endothelial cells to promote robust angiogenesis. In vitro, this cooperative environment significantly enhanced osteogenic differentiation and vascular network formation. In vivo application in a rat critical‐sized calvarial defect model validated the hydrogel's therapeutic efficacy. At 8 weeks, the composite system increased the bone volume fraction (BV/TV) by 21.07% compared to a commercial bone repair material, accompanied by extensive neovascularization. This multifunctional hydrogel establishes a synchronized, translatable strategy for advanced tissue engineering.
- 12 October 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (40) , e71772
Open AccessCooperative Stem Cell Homing and Photothermal Protection Driven by an Injectable Hydrogel for Bone‐Vascular Regeneration
Bone defects caused by trauma or disease present significant clinical challenges, necessitating advanced biomaterials that simultaneously recruit stem cells and orchestrate a conducive microenvironment for repair. Here, we present an injectable hydrogel system designed to drive integrated bone‐vascular regeneration through targeted stem cell homing and localized metabolic rescue. The composite hydrogel, crosslinked from gelatin and oxidized starch, integrates liposome‐encapsulated stromal cell‐derived factor‐1 (SDF‐1) and MXene‐enabled GelMA microspheres. This minimally invasive system addresses two critical regenerative phases. First, liposomal SDF‐1 undergoes controlled release to effectively recruit endogenous bone marrow mesenchymal stem cells (BMSCs). Concurrently, under near‐infrared irradiation, the MXene‐GelMA microspheres generate mild localized heat stress (40—42 °C). Crucially, this targeted photothermal therapy acts as a metabolic rescue mechanism; it upregulates heat shock protein 70 (HSP70) in BMSCs to mitigate apoptosis, stimulating endothelial cells to promote robust angiogenesis. In vitro, this cooperative environment significantly enhanced osteogenic differentiation and vascular network formation. In vivo application in a rat critical‐sized calvarial defect model validated the hydrogel's therapeutic efficacy. At 8 weeks, the composite system increased the bone volume fraction (BV/TV) by 21.07% compared to a commercial bone repair material, accompanied by extensive neovascularization. This multifunctional hydrogel establishes a synchronized, translatable strategy for advanced tissue engineering.
- Open Access
- 6 September 2026
- Published by Wiley in Advanced Science
- Vol. 13 (64) , e77385
Matrix Stiffness Orchestrates Mesenchymal Stem Cell Lineage Commitment Toward Osteogenesis and Adipogenesis Through the PIEZO1/SP1/STC2 Axis
Mesenchymal stem cells (MSCs) are critical for bone regeneration, and their osteogenic and adipogenic lineage balance is intricately regulated by cellular mechanotransduction. Through single‐cell RNA sequencing reanalysis of the public dataset GSE166824, primary mouse MSC functional assays, and in vivo genetic and bone defect models, this study identifies a novel PIEZO1/specificity protein 1 (SP1)/stanniocalcin 2 (STC2) signaling axis that drives matrix stiffness‐dependent MSC lineage commitment. Stiff matrices robustly direct MSCs toward osteogenic differentiation while inhibiting adipogenesis by activating the mechanosensitive ion channel PIEZO1. PIEZO1 activation triggers Ca 2 + influx, leading to calcium/calmodulin‐dependent protein kinase II (CaMKII)‐dependent SP1 activation. SP1 shows enrichment at the promoter region of Stc2 and upregulates its expression. The secreted protein STC2 functions downstream of PIEZO1 on stiff matrices while retaining pro‐osteogenic and anti‐adipogenic activity when PIEZO1 remains inactive. In a mouse femoral bone defect model under hindlimb unloading, both stiff gelatin methacryloyl (GelMA) hydrogels and exogenous STC2 administration enhance early‐stage bone formation on day 7. Conversely, Prrx1 ‐lineage‐specific inducible conditional knockout (iCKO) of Piezo1 abrogates the regulatory effects of matrix stiffness. These findings establish the PIEZO1/SP1/STC2 axis as a pivotal mechanosensitive signaling pathway for MSC fate determination, offering novel molecular targets for mechanically optimized bone regenerative biomaterials.
- 6 September 2026
- Published by Wiley in Advanced Science
- Vol. 13 (64) , e77385
Open AccessMatrix Stiffness Orchestrates Mesenchymal Stem Cell Lineage Commitment Toward Osteogenesis and Adipogenesis Through the PIEZO1/SP1/STC2 Axis
Mesenchymal stem cells (MSCs) are critical for bone regeneration, and their osteogenic and adipogenic lineage balance is intricately regulated by cellular mechanotransduction. Through single‐cell RNA sequencing reanalysis of the public dataset GSE166824, primary mouse MSC functional assays, and in vivo genetic and bone defect models, this study identifies a novel PIEZO1/specificity protein 1 (SP1)/stanniocalcin 2 (STC2) signaling axis that drives matrix stiffness‐dependent MSC lineage commitment. Stiff matrices robustly direct MSCs toward osteogenic differentiation while inhibiting adipogenesis by activating the mechanosensitive ion channel PIEZO1. PIEZO1 activation triggers Ca 2 + influx, leading to calcium/calmodulin‐dependent protein kinase II (CaMKII)‐dependent SP1 activation. SP1 shows enrichment at the promoter region of Stc2 and upregulates its expression. The secreted protein STC2 functions downstream of PIEZO1 on stiff matrices while retaining pro‐osteogenic and anti‐adipogenic activity when PIEZO1 remains inactive. In a mouse femoral bone defect model under hindlimb unloading, both stiff gelatin methacryloyl (GelMA) hydrogels and exogenous STC2 administration enhance early‐stage bone formation on day 7. Conversely, Prrx1 ‐lineage‐specific inducible conditional knockout (iCKO) of Piezo1 abrogates the regulatory effects of matrix stiffness. These findings establish the PIEZO1/SP1/STC2 axis as a pivotal mechanosensitive signaling pathway for MSC fate determination, offering novel molecular targets for mechanically optimized bone regenerative biomaterials.
- Open Access
- 4 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1679987
Deciphering oligomeric proanthocyanidins’ dual osteoprotective mechanisms at single-cell resolution: NR4A1-mediated PTGS2 suppression and β-catenin-Runx2 activation
Background: Osteoporosis (OP), as a systemic bone disorder, has a complex pathogenesis and faces significant challenges in clinical treatment. Oligomeric proanthocyanidin (OPC), a type of natural polyphenolic flavonoid compound, demonstrates outstanding therapeutic potential due to its excellent antioxidant and anti-inflammatory properties and good safety. The breakthrough advances in single-cell RNA sequencing (scRNA-seq) technology have provided a powerful research tool for elucidating the multitarget mechanisms of OPC in the treatment of OP. Methods: This study first screened the active components of OPC leveraging the TCMSP database. The protein–protein interaction network of OPC target proteins was generated through the STRING database, and visual analysis was accomplished using the Cytoscape software. The ClusterProfiler R package and ClueGO plugin were employed for functional enrichment analysis and network visualization. At the same time, scRNA-seq data from the GEO database were integrated, and cell-type identification was attained using the Seurat tool. The differentiation trajectories of subtypes were inferred using Monocle and Slingshot software. The cell communication network was analyzed using CellChat. Results: This study utilized scRNA-seq to identify C2 NR4A1 + MSCs with distinct metabolic features and differentiation potential in the bone microenvironment during the early stage of OP, namely, osteopenia. The natural component OPC can precisely target this subtype and exert therapeutic effects through two mechanisms: inhibiting the transcriptional activity of NR4A1 to suppress the expression of PTGS2 in MSCs and simultaneously activating the β-catenin-dependent NR4A1 – Runx2 signaling axis to promote osteogenesis and inhibit osteoclastogenesis. These findings establish a new therapeutic paradigm of “targeting cell subtypes–multipathway regulation,” providing an important basis for the development of novel anti-OP drugs. Conclusion: Our research integrated multilevel approaches, including single-cell transcriptomics, network pharmacology, cellular experiments, and animal models, to systematically reveal the dual mechanism of OPC in treating OP. This discovery not only established C2 NR4A1 + MSCs as key mediators in the pathological process of OP but also clarified the molecular mechanism of multitarget synergy of natural active compounds in restoring bone homeostasis, providing a theoretical basis and practical guidance for the development of new OP therapies.
- 4 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1679987
Open AccessDeciphering oligomeric proanthocyanidins’ dual osteoprotective mechanisms at single-cell resolution: NR4A1-mediated PTGS2 suppression and β-catenin-Runx2 activation
Background: Osteoporosis (OP), as a systemic bone disorder, has a complex pathogenesis and faces significant challenges in clinical treatment. Oligomeric proanthocyanidin (OPC), a type of natural polyphenolic flavonoid compound, demonstrates outstanding therapeutic potential due to its excellent antioxidant and anti-inflammatory properties and good safety. The breakthrough advances in single-cell RNA sequencing (scRNA-seq) technology have provided a powerful research tool for elucidating the multitarget mechanisms of OPC in the treatment of OP. Methods: This study first screened the active components of OPC leveraging the TCMSP database. The protein–protein interaction network of OPC target proteins was generated through the STRING database, and visual analysis was accomplished using the Cytoscape software. The ClusterProfiler R package and ClueGO plugin were employed for functional enrichment analysis and network visualization. At the same time, scRNA-seq data from the GEO database were integrated, and cell-type identification was attained using the Seurat tool. The differentiation trajectories of subtypes were inferred using Monocle and Slingshot software. The cell communication network was analyzed using CellChat. Results: This study utilized scRNA-seq to identify C2 NR4A1 + MSCs with distinct metabolic features and differentiation potential in the bone microenvironment during the early stage of OP, namely, osteopenia. The natural component OPC can precisely target this subtype and exert therapeutic effects through two mechanisms: inhibiting the transcriptional activity of NR4A1 to suppress the expression of PTGS2 in MSCs and simultaneously activating the β-catenin-dependent NR4A1 – Runx2 signaling axis to promote osteogenesis and inhibit osteoclastogenesis. These findings establish a new therapeutic paradigm of “targeting cell subtypes–multipathway regulation,” providing an important basis for the development of novel anti-OP drugs. Conclusion: Our research integrated multilevel approaches, including single-cell transcriptomics, network pharmacology, cellular experiments, and animal models, to systematically reveal the dual mechanism of OPC in treating OP. This discovery not only established C2 NR4A1 + MSCs as key mediators in the pathological process of OP but also clarified the molecular mechanism of multitarget synergy of natural active compounds in restoring bone homeostasis, providing a theoretical basis and practical guidance for the development of new OP therapies.
- 30 October 2025
- Published by Elsevier in Carbohydrate Polymers
- Vol. 373, 124609
Hydroxybutyl chitosan-based thermosensitive hydrogel enhanced osteoporotic bone regeneration through sustained release of alendronate and BMP-2
- 30 October 2025
- Published by Elsevier in Carbohydrate Polymers
- Vol. 373, 124609
Hydroxybutyl chitosan-based thermosensitive hydrogel enhanced osteoporotic bone regeneration through sustained release of alendronate and BMP-2
- Open Access
- 1 July 2025
- Published by Springer Nature in Advanced Composites and Hybrid Materials
- Vol. 8 (4) , 1-35
Advances in artificial ligament biomaterials for anterior cruciate ligament reconstruction: material innovation, surface modification, and novel adjuvant methods
- 1 July 2025
- Published by Springer Nature in Advanced Composites and Hybrid Materials
- Vol. 8 (4) , 1-35
Open AccessAdvances in artificial ligament biomaterials for anterior cruciate ligament reconstruction: material innovation, surface modification, and novel adjuvant methods
- Top Cited PapersOpen Access
- 18 December 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-23
New insights into the role of mitophagy related gene affecting the metastasis of osteosarcoma through scRNA-seq and CRISPR-Cas9 genome editing
Osteosarcoma (OSA), the most common primary bone malignancy, poses significant challenges due to its aggressive nature and propensity for metastasis, especially in adolescents. Mitophagy analysis can help identify new therapeutic targets and combined treatment strategies. This study integrates single-cell sequencing (scRNA-seq) data and bulk-seq to identify mitophagy-related genes (MRGs) associated with the progression of OSA metastasis and analyze their clinical significance. scRNA-seq data elucidates the relationship between mitophagy and OSA metastasis, employing “CellChat” R package to explore intercellular communications and report on hundreds of ligand-receptor interactions. Subsequently, the combination of bulk-seq and CRISPR-Cas9 gene editing identifies mitophagy-related biomarker associated with metastatic prognosis. Finally, validation of the relationship between mitophagy and OSA metastasis is achieved through cellular biology experiments and animal studies. The distinct mitophagy activity of various mitochondria manifests in diverse spatial localization, cellular developmental trajectories, and intercellular interactions. OSA tissue exhibits notable heterogeneity in mitophagy within osteoblastic OSA cells. However, high mitophagy activity correlates consistently with high metastatic potential. Subsequently, we identified three critical genes associated with mitophagy in OSA, namely RPS27A, TOMM20 and UBB. According to the aforementioned queue of genes, we have constructed a mitophagy_score (MIP_score). We observed that it consistently predicts patient prognosis in both internal and external datasets, demonstrating strong robustness and stability. Furthermore, we have found that MIP_score can also guide chemotherapy, with varying sensitivities to chemotherapeutic agents based on different MIP_score. It is noteworthy that, through the integration of CRISPR-Cas9 genome-wide screening and validation via cellular and animal experiments, we have identified RPS27A as a potential novel biomarker for OSA. Our comprehensive analysis elucidated the profile of mitophagy throughout the OSA metastasis process, forming the basis for a mitophagy-related prognostic model that addresses clinical outcomes and drug sensitivity following OSA metastasis. Additionally, an online interactive platform was established to assist clinicians in decision-making ( https://mip-score.shinyapps.io/labtan/ ). These findings lay the groundwork for developing targeted therapies aimed at improving the prognosis of OSA patients.
- 18 December 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-23
Top Cited PapersOpen AccessNew insights into the role of mitophagy related gene affecting the metastasis of osteosarcoma through scRNA-seq and CRISPR-Cas9 genome editing
Osteosarcoma (OSA), the most common primary bone malignancy, poses significant challenges due to its aggressive nature and propensity for metastasis, especially in adolescents. Mitophagy analysis can help identify new therapeutic targets and combined treatment strategies. This study integrates single-cell sequencing (scRNA-seq) data and bulk-seq to identify mitophagy-related genes (MRGs) associated with the progression of OSA metastasis and analyze their clinical significance. scRNA-seq data elucidates the relationship between mitophagy and OSA metastasis, employing “CellChat” R package to explore intercellular communications and report on hundreds of ligand-receptor interactions. Subsequently, the combination of bulk-seq and CRISPR-Cas9 gene editing identifies mitophagy-related biomarker associated with metastatic prognosis. Finally, validation of the relationship between mitophagy and OSA metastasis is achieved through cellular biology experiments and animal studies. The distinct mitophagy activity of various mitochondria manifests in diverse spatial localization, cellular developmental trajectories, and intercellular interactions. OSA tissue exhibits notable heterogeneity in mitophagy within osteoblastic OSA cells. However, high mitophagy activity correlates consistently with high metastatic potential. Subsequently, we identified three critical genes associated with mitophagy in OSA, namely RPS27A, TOMM20 and UBB. According to the aforementioned queue of genes, we have constructed a mitophagy_score (MIP_score). We observed that it consistently predicts patient prognosis in both internal and external datasets, demonstrating strong robustness and stability. Furthermore, we have found that MIP_score can also guide chemotherapy, with varying sensitivities to chemotherapeutic agents based on different MIP_score. It is noteworthy that, through the integration of CRISPR-Cas9 genome-wide screening and validation via cellular and animal experiments, we have identified RPS27A as a potential novel biomarker for OSA. Our comprehensive analysis elucidated the profile of mitophagy throughout the OSA metastasis process, forming the basis for a mitophagy-related prognostic model that addresses clinical outcomes and drug sensitivity following OSA metastasis. Additionally, an online interactive platform was established to assist clinicians in decision-making ( https://mip-score.shinyapps.io/labtan/ ). These findings lay the groundwork for developing targeted therapies aimed at improving the prognosis of OSA patients.
- Open Access
- 1 December 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 42, 85-111
Novel injectable adhesive hydrogel loaded with exosomes for holistic repair of hemophilic articular cartilage defect
Hemophilic articular cartilage damage presents a significant challenge for surgeons, characterized by recurrent intraarticular bleeding, a severe inflammatory microenvironment, and limited self-repair capability of cartilage tissue. Currently, there is a lack of tissue engineering-based integrated therapies that address both early hemostasis, anti-inflammation, and long-lasting chondrogenesis for hemophilic articular cartilage defects. Herein, we developed an adhesive hydrogel using oxidized chondroitin sulfate and gelatin, loaded with exosomes derived from bone marrow stem cells (BMSCs) (Hydrogel-Exos). This hydrogel demonstrated favorable injectability, self-healing, biocompatibility, biodegradability, swelling, frictional and mechanical properties, providing a comprehensive approach to treating hemophilic articular cartilage defects. The adhesive hydrogel, featuring dynamic Schiff base bonds and hydrogen bonds, exhibited excellent wet tissue adhesiveness and hemostatic properties. In a pig model, the hydrogel could be smoothly injected into the knee joint cartilage defect site and gelled in situ under fluid-irrigated arthroscopic conditions. Our in vitro and in vivo experiments confirmed that the sustained release of exosomes yielded anti-inflammatory effects by modulating macrophage M2 polarization through the NF-κB pathway. This immunoregulatory effect, coupled with the extracellular matrix components provided by the adhesive hydrogel, enhanced chondrogenesis, promoted the cartilage repair and joint function restoration after hemophilic articular cartilage defects. In conclusion, our results highlight the significant application potential of Hydrogel-Exos for early hemostasis, immunoregulation, and long-term chondrogenesis in hemophilic patients with cartilage injuries. This innovative approach is well-suited for application during arthroscopic procedures, offering a promising solution for addressing the complex challenges associated with hemophilic articular cartilage damage.
- 1 December 2024
- Published by KEAI Publishing in Bioactive Materials
- Vol. 42, 85-111
Open AccessNovel injectable adhesive hydrogel loaded with exosomes for holistic repair of hemophilic articular cartilage defect
Hemophilic articular cartilage damage presents a significant challenge for surgeons, characterized by recurrent intraarticular bleeding, a severe inflammatory microenvironment, and limited self-repair capability of cartilage tissue. Currently, there is a lack of tissue engineering-based integrated therapies that address both early hemostasis, anti-inflammation, and long-lasting chondrogenesis for hemophilic articular cartilage defects. Herein, we developed an adhesive hydrogel using oxidized chondroitin sulfate and gelatin, loaded with exosomes derived from bone marrow stem cells (BMSCs) (Hydrogel-Exos). This hydrogel demonstrated favorable injectability, self-healing, biocompatibility, biodegradability, swelling, frictional and mechanical properties, providing a comprehensive approach to treating hemophilic articular cartilage defects. The adhesive hydrogel, featuring dynamic Schiff base bonds and hydrogen bonds, exhibited excellent wet tissue adhesiveness and hemostatic properties. In a pig model, the hydrogel could be smoothly injected into the knee joint cartilage defect site and gelled in situ under fluid-irrigated arthroscopic conditions. Our in vitro and in vivo experiments confirmed that the sustained release of exosomes yielded anti-inflammatory effects by modulating macrophage M2 polarization through the NF-κB pathway. This immunoregulatory effect, coupled with the extracellular matrix components provided by the adhesive hydrogel, enhanced chondrogenesis, promoted the cartilage repair and joint function restoration after hemophilic articular cartilage defects. In conclusion, our results highlight the significant application potential of Hydrogel-Exos for early hemostasis, immunoregulation, and long-term chondrogenesis in hemophilic patients with cartilage injuries. This innovative approach is well-suited for application during arthroscopic procedures, offering a promising solution for addressing the complex challenges associated with hemophilic articular cartilage damage.
- Open Access
- 6 October 2023
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2023, 1-16
Flavonoids from Lophatherum gracile Brongn. Ameliorate Liver Damages in High-Fat Diet and Streptozotocin-Induced Diabetic Mice by Regulating PI3K/AKT and NF-Kappa B Pathways
Inflammation and metabolic disorders are crucial factors that induce type 2 diabetes mellitus (T2DM). Lophatherum gracile Brongn. (L. gracile) has been popularly consumed as folk medicine and dietary supplement for the treatment of fever and inflammatory-associated diseases. Flavonoids are the major constituents of L. gracile with various pharmacological effects. However, the protective effects of flavonoids from leaves of L. gracile against T2DM, as well as the potential mechanisms, were not yet elucidated. In the present study, the total flavonoid content of L. gracile (LGBF) with higher flavonoid content and pancreas lipase inhibitory activity was extracted and screened from the leaves of L. gracile. Twelve flavonoid compounds were identified in LGBF by liquid LC-MS analysis. Network pharmacology identified seven potential flavonoid compounds and 10 core targets associated with T2DM. GO and KEGG pathway enrichment analysis indicated that PI3K/AKT and inflammation-related pathways might occupy core status. Molecular docking results showed that the active constituents of LGBF had a good binding activity with key targets. Furthermore, high-fat diet (HFD) and streptozotocin (STZ)-induced diabetic mice were developed and treated with LGBF for experimental validation. The data showed that LGBF intervention potently improved the lipid profiles and insulin sensitivity of HFD and STZ-induced mice. Hepatic inflammation and lipid accumulation were also partially reversed by LGBF intervention. Further assays confirmed that LGBF administration significantly increased PI3K and AKT phosphorylation, while reducing IL-1β expression and NF-κB P65 phosphorylation in the liver of mice. In conclusion, LGBF administration could relieve liver damage in diabetic mice via regulating PI3K/AKT and NF-κB pathways.
- 6 October 2023
- Published by Wiley in Journal of Food Biochemistry
- Vol. 2023, 1-16
Open AccessFlavonoids from Lophatherum gracile Brongn. Ameliorate Liver Damages in High-Fat Diet and Streptozotocin-Induced Diabetic Mice by Regulating PI3K/AKT and NF-Kappa B Pathways
Inflammation and metabolic disorders are crucial factors that induce type 2 diabetes mellitus (T2DM). Lophatherum gracile Brongn. (L. gracile) has been popularly consumed as folk medicine and dietary supplement for the treatment of fever and inflammatory-associated diseases. Flavonoids are the major constituents of L. gracile with various pharmacological effects. However, the protective effects of flavonoids from leaves of L. gracile against T2DM, as well as the potential mechanisms, were not yet elucidated. In the present study, the total flavonoid content of L. gracile (LGBF) with higher flavonoid content and pancreas lipase inhibitory activity was extracted and screened from the leaves of L. gracile. Twelve flavonoid compounds were identified in LGBF by liquid LC-MS analysis. Network pharmacology identified seven potential flavonoid compounds and 10 core targets associated with T2DM. GO and KEGG pathway enrichment analysis indicated that PI3K/AKT and inflammation-related pathways might occupy core status. Molecular docking results showed that the active constituents of LGBF had a good binding activity with key targets. Furthermore, high-fat diet (HFD) and streptozotocin (STZ)-induced diabetic mice were developed and treated with LGBF for experimental validation. The data showed that LGBF intervention potently improved the lipid profiles and insulin sensitivity of HFD and STZ-induced mice. Hepatic inflammation and lipid accumulation were also partially reversed by LGBF intervention. Further assays confirmed that LGBF administration significantly increased PI3K and AKT phosphorylation, while reducing IL-1β expression and NF-κB P65 phosphorylation in the liver of mice. In conclusion, LGBF administration could relieve liver damage in diabetic mice via regulating PI3K/AKT and NF-κB pathways.